CTOs on the Move

Actuate Therapeutics

www.actuatetherapeutics.com

 
Actuate Therapeutics, Inc. is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Actuate Therapeutics raised $21.7M on 05/17/2019
Actuate Therapeutics raised $14.4M on 12/10/2020

Similar Companies

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shape Therapeutics

Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.

Karius

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.

Predicine

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology and infectious diseases, including COVID-19. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, Berlin and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.